An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
Cemiplimab (Libtayo): CADTH Reimbursement Recommendation: Indication: For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Mar.
Pertuzumab (Perjeta): CADTH Reimbursement Recommendation: Indication: In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early-stage breast cancer (either 2 cm in diameter or node positive) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.
Early and locally advanced breast cancer: diagnosis and management.
London: National Institute for Health and Care Excellence (NICE); 2024 Jan 16. (NICE Guideline, No. 101.)
Pemigatinib (Pemazyre): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Apr.
Polatuzumab Vedotin (Polivy): CADTH Reimbursement Recommendation: Indication: Large B-cell lymphoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (combined positive score ≥ 1), as determined by a validated test, in combination with chemotherapy with or without bevacizumab [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Dec.
Eptinezumab (Vyepti): CADTH Reimbursement Recommendation: Indication: Indicated for the prevention of migraine in adults who have had at least 4 migraine days per month [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Atezolizumab (Tecentriq): CADTH Reimbursement Recommendation: Indication: In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer [Internet].
Sotorasib (Lumakras): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Kirsten rat sarcoma viral oncogene homologue (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) who have received at least one prior systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: In combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer who have not received prior chemotherapy for metastatic disease and whose tumours express programmed cell death-ligand 1 (combined positive score ≥ 10) as determined by a validated test [Internet].
Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults.
Geneva: World Health Organization; 2014.
Avacopan (Tavneos): CADTH Reimbursement Recommendation: Indication: For the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard background therapy including glucocorticoids. Avacopan does not eliminate glucocorticoid use [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug.
Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2011 Apr. (NICE Clinical Guidelines, No. 122.)
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)
Improving Palliative Care for Cancer: Summary and Recommendations.
Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board; Foley KM, Gelband H, editors.
Washington (DC): National Academies Press (US); 2001.
Alpelisib (Piqray): CADTH Reimbursement Recommendation: Indication: In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [Internet].
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on